Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

Table 7

Efficacy end points in intent-to-treat population, adapted from Geyer et al. [40].

End point	Lapatinib plus capecitabine	Capecitabine alone	Hazard ratio	P-value
	(N = 163)	(N = 161)	(95% CI)
Median time to progression—mo	8.4	4.4	0.49 (0.34–0.71)	<.001^†
Median progression-free survival—mo	8.4	4.1	0.47 (0.33–0.67)	<.001^†
Overall response—% (95% CI)	22 (16–29)	14 (9–21)		.09^‡
Complete response—no. (%)	1 (<1)	0 (0)
Partial response—no. (%)	35 (21)	23 (14)
Clinical benefit—no. (%)	44 (27)	29 (18)
Death—no. (%)	36 (22)	35 (22)

End Points are based on evaluation by the independent review committee under blinded conditions.
^†The P-value was calculated with the log-rank test.
^‡The P-value was calculated with Fisher’s exact test.